Avelas starts Phase II of imaging agent AVB-620 in patients with primary breast cancer

Avelas Biosciences Inc. (La Jolla, Calif.) began a Phase II trial to evaluate a single dose of IV AVB-620 administered prior to surgery to detect malignant tissue in about 100 women with primary, non-recurrent, non-metastatic breast cancer undergoing surgery.

The open-label, U.S. trial has 2 periods. The first will evaluate conditions affecting detection in about 30 patients. The second will then evaluate the primary endpoint of AVB-620 imaging accuracy in distinguishing malignant from non-malignant tissues in about 70 patients...